NCT02326974 - T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA | Biotech Hunter

Enrollment

164

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

June 30, 2018

Study Completion Date

January 31, 2028

Conditions

HER-2 Positive Breast CancerBreast CancerStage II Breast CancerStage III Breast Cancer

Interventions

DRUG

T-DM1

Neoadjuvant treatment is for a total of 18 weeks.

DRUG

Pertuzumab

Neoadjuvant treatment is for a total of 18 weeks.

PROCEDURE

Excision of tumor/mastectomy

Definitive breast cancer surgery (excision or mastectomy) marks the end of protocol mandated therapy.

Trial Locations (4)

Tennessee Oncology/Sarah Cannon Research Institute, Nashville

Vanderbilt-Ingram Cancer Center, Nashville

Massachusetts General Hospital, Boston

Dana Farber Cancer Institute, Boston